产品说明书
Brevilin A
 |
同义名 : | 6-O-Angeloylprenolin;6-O-Angeloylplenolina;6-O-Angeloylplenolin;6-OAP;Brevelin A |
| CAS号 : | 16503-32-5 | |
| 货号 : | A426347 | |
| 分子式 : | C20H26O5 | |
| 纯度 : | 98% | |
| 分子量 : | 346.418 | |
| MDL号 : | MFCD04034623 | |
| 存储条件： |
粉末 Sealed in dry,2-8°C 液体 -20°C:3-6个月-80°C:12个月 |
|
| 溶解度 : |
DMSO: 105 mg/mL(303.1 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO |
|
| 动物实验配方： |
| 生物活性 | |||
|---|---|---|---|
| 描述 | STAT3 is an oncoprotein which participates in essential processes of cell survival, growth and proliferation in many types of tumors, as well as immune diseases[3]. Brevilin A is a sesquiterpene lactone isolated from Centipeda minima with anti-tumor activity. Brevilin A is a selective inhibitor of JAK-STAT signal pathway by attenuating the JAKs activity and blocking STAT3 signaling (IC50 = 10.6 µM) in cancer cells[3]. In vivo investigation suggested that brevilin A significantly inhibited the growth of CT26 tumor compared to adriamycin and concurrently promoted the expressions of LC3-II and cleaved-caspase-3 in tumor tissues[4]. Brevilin A increased ROS levels, decreased MMP and induced apoptosis of CT26 cell in a dose-dependent manner. Higher apoptotic rates were achieved in CT26 cells treated with 2 μg/ml brevilin A compared to 2 μg/ml adriamycin, with a statistical significance of both compounds compared to control, indicating that brevilin A exerts a greater capacity in cell apoptosis induction than adriamycin[4]. Brevilin A significantly down-regulated the phosphorylation of PI3K, AKT and mTOR, and promoted the expression of LC3-II, which was a key protein in cell autophagy, in addition to the expression of autophagy-related proteins Beclin1 and Atg5, which indicated that PI3K/AKT/mTOR signaling was involved in CT26 autophagy induced by brevilin A[4]. Tumor weights of mice treated with brevilin A and adriamycin for 14 days were significantly lower compared to the control group (p < .01, p < .05) while the weight of those treated with brevilin A were significantly lower than that of the adriamycin group (p < .01). Body weights in adriamycin group were clearly lower than brevilin A group (p < .01), indicating that brevilin A exhibites lower toxicity compared to adriamycin[4]. The growth inhibition of the tumors by brevilin A reached 74.89% on day 14 after the inoculation, but the inhibition of tumor growth by adriamycin was 53.18%. In contrast with the control, brevilin A significantly promoted the expressions of LC3-II and cleaved-caspase-3 in tumor tissues[4]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
2.89mL 0.58mL 0.29mL |
14.43mL 2.89mL 1.44mL |
28.87mL 5.77mL 2.89mL |
| 参考文献 |
|---|